Barclays Maintains 10x Genomics(TXG.US) With Buy Rating, Cuts Target Price to $19

巴克萊銀行維持10x Genomics(TXG.US)買入評級，下調目標價至19美元

富途資訊 · 2024/11/01 15:32 · 評級/大行評級

Barclays analyst Luke Sergott maintains $10x Genomics (TXG.US)$ with a buy rating, and adjusts the target price from $21 to $19.

According to TipRanks data, the analyst has a success rate of 39.8% and a total average return of -4.8% over the past year.

AnalystRecentRatingAutoNews_77919296901262_20241101_dcf47a6135bee0f16c87ee9e8915d0c296aba6e6_1730561431932067_nn_en

Furthermore, according to the comprehensive report, the opinions of $10x Genomics (TXG.US)$'s main analysts recently are as follows:

10x Genomics endured a challenging quarter influenced by a commercial reorganization and a subdued genomics capital expenditure environment. It is anticipated that this period represents the low point of the demand environment, and the restructuring is expected to begin yielding modest improvements as genomics capital expenditure demand starts to recover.
Following the Q3 report, 10x Genomics has seen an adjustment in the fiscal 2024 guidance, reduced by $50M at the midpoint, indicating a forecast for flat sequential revenue in Q4, which falls short of the general consensus. The recent weakness is primarily ascribed to disruptions caused by commercial and organizational transitions, compounded by tough macroeconomic conditions.

Note:

TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.

Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.

TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.

巴克萊銀行分析師Luke Sergott維持$10x Genomics (TXG.US)$買入評級，並將目標價從21美元下調至19美元。

根據TipRanks數據顯示，該分析師近一年總勝率為39.8%，總平均回報率為-4.8%。

AnalystRecentRatingAutoNews_77919296901262_20241101_dcf47a6135bee0f16c87ee9e8915d0c296aba6e6_1730561431932067_nn_tc

此外，綜合報道，$10x Genomics (TXG.US)$近期主要分析師觀點如下：

受商業重組和低迷的基因組資本支出環境的影響，10x Genomics經歷了一個充滿挑戰的季度。預計這一時期是需求環境的低點，隨着基因組學資本支出需求開始恢復，預計重組將開始產生適度的改善。
繼第三季度報告發布後，10x Genomics調整了2024財年的指導方針，在中點減少了5000萬美元，這表明預計第四季度連續收入將持平，未達到普遍共識。最近的疲軟主要歸因於商業和組織轉型造成的混亂，再加上艱難的宏觀經濟狀況。

提示:

TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。

TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。

分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。

總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。

譯文內容由第三人軟體翻譯。

以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。

Barclays Maintains 10x Genomics(TXG.US) With Buy Rating, Cuts Target Price to $19

Barclays Maintains 10x Genomics(TXG.US) With Buy Rating, Cuts Target Price to $19

風險及免責聲明

聲明